Actinium Pharmaceuticals Inc ATNM

$1.43 0.00 (—)

Valuation

Market cap: 46,533,000
Revenue TTM: $90,000
Net income TTM: $-33,890,000
P/E (trailing): 4.25
P/E (forward): 8.27
Profit margin: -37,655.55%
Debt to equity: 0.00

Trading

Volume: 24,939
Avg volume: 179,566
Day's range: $1.40 – $1.46
Shares out: 31,441,000
Stochastic %K: 30%
Beta: 0.26
Analysts: Strong Buy
Price target: $3.60

Price

Company profile

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Industry: Biotechnology
Sector: Healthcare
Phone: 646 677 3870
Website: https://www.actiniumpharma.com
Address: 100 Park Avenue, 23rd Floor, New York, United States

Latest news

Nov 2, 2026, 8:00 AM EST · 1 day ago

Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models

Oct 30, 2026, 5:15 PM EDT · 3 days ago

Actinium Pharmaceuticals Announces Inducement Grant to New Employee

Oct 23, 2026, 8:00 AM EDT · 11 days ago

Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026

2026-10-20T12:11:04.000Z · 14 days ago

Actinium Pharmaceuticals’ ATNM-400 shows anti-tumor activity in prostate cancer

Oct 20, 2026, 8:00 AM EDT · 14 days ago

Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer

Oct 20, 2026, 7:30 AM EDT · 14 days ago

Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models

Oct 19, 2026, 7:30 AM EDT · 15 days ago

Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026

Oct 16, 2026, 5:00 PM EDT · 17 days ago

Actinium Pharmaceuticals Announces Inducement Grants to New Employees

2026-10-16T12:35:49.000Z · 18 days ago

Actinium Pharmaceuticals to present ATNM-400 data at EANM

Oct 16, 2026, 8:30 AM EDT · 18 days ago

Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models

Oct 16, 2026, 7:30 AM EDT · 18 days ago

Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

Oct 15, 2026, 8:30 AM EDT · 19 days ago

Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer

2026-10-15T11:40:53.000Z · 19 days ago

Actinium Pharmaceuticals appoints Matt David as CFO

Oct 15, 2026, 7:30 AM EDT · 19 days ago

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

CRMD OVID

Sep 4, 2026, 5:05 PM EDT · 1 month ago

Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Aug 14, 2026, 5:02 PM EDT · 2 months ago

Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update

2026-06-03T13:39:19.000Z · 5 months ago

Actinium presented preclinical data on ATNM-400 in NSCLC at SNMMI 2026

Jun 3, 2026, 8:00 AM EDT · 5 months ago

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Jun 3, 2026, 7:25 AM EDT · 5 months ago

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models

2026-06-01T12:52:17.000Z · 5 months ago

Actinium Pharmaceuticals names Steffen Heeger MD, MSc as Chief Medical Officer

Jun 1, 2026, 8:00 AM EDT · 5 months ago

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

CNTA

2026-06-01T11:12:02.000Z · 5 months ago

Actinium Pharmaceuticals presents new radiochemistry data at SNMMI

Jun 1, 2026, 7:00 AM EDT · 5 months ago

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

2026-05-29T21:41:04.000Z · 5 months ago

Actinium Pharmaceuticals receives two patent allowances from CIPO

May 29, 2026, 5:31 PM EDT · 5 months ago

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

May 29, 2026, 5:30 PM EDT · 5 months ago

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

May 27, 2026, 9:00 AM EDT · 5 months ago

NorthStar and QSA Global Announce Multi-Year Strategic Partnership to Strengthen Actinium-225 Supply Chain for Targeted Alpha Therapies

May 6, 2026, 8:00 AM EDT · 6 months ago

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

2026-04-22T11:29:41.000Z · 6 months ago

Actinium presents data from Actimab-A studies at AACR

2026-04-22T11:23:31.000Z · 6 months ago

Actinium presents preclinical results for ATNM-400 at AACR

Apr 22, 2026, 7:00 AM EDT · 6 months ago

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

Apr 22, 2026, 7:00 AM EDT · 6 months ago

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

Apr 15, 2026, 8:00 AM EDT · 6 months ago

NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225

Apr 6, 2026, 7:30 AM EDT · 7 months ago

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

Feb 17, 2026, 8:00 AM EST · 8 months ago

BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research

2025-12-12T13:50:27.000Z · 10 months ago

Actinium Pharmaceuticals presents new data on anti-tumor activity of ATNM-400

Dec 12, 2025, 8:45 AM EST · 10 months ago

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

2025-12-01T13:50:36.000Z · 11 months ago

Actinium Pharmaceuticals announces preclinical data for ATNM-400

Dec 1, 2025, 8:45 AM EST · 11 months ago

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

Nov 17, 2025, 8:30 AM EST · 11 months ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

NVS

2025-10-27T11:15:51.000Z · 1 year ago

Actinium Pharmaceuticals’ ATNM-400 shows superior anti-tumor activity

AZN JNJ

Oct 27, 2025, 7:00 AM EDT · 1 year ago

Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2025-10-24T12:35:37.000Z · 1 year ago

Actinium presents preclinical data for ATNM-400

Oct 24, 2025, 8:30 AM EDT · 1 year ago

Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

2025-10-13T16:25:11.000Z · 1 year ago

Actinium Pharmaceuticals to announces preclinical data from ATNM-400 program

Oct 13, 2025, 12:10 PM EDT · 1 year ago

Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 8:30 AM EDT · 1 year ago

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

2025-07-31T12:42:35.000Z · 1 year ago

Actinium Pharmaceuticals’ ATNM-400 shows improved survival in prostate cancer

Jul 31, 2025, 8:30 AM EDT · 1 year ago

Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit

2025-06-23T17:33:54.000Z · 1 year ago

Actinium highlights expanded data set for ATNM-400 in prostate cancer

Jun 23, 2025, 11:30 AM EDT · 1 year ago

Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting

2025-05-20T12:31:41.000Z · 1 year ago

ATNM Lawsuit Alert! Class Action Lawsuit Against Actinium Pharmaceuticals

2025-05-06T12:50:27.000Z · 1 year ago

Actinium enrolls first patient on the trial studying Iomab-ACT

2025-04-28T12:47:44.000Z · 1 year ago

Actinium Pharmaceuticals’ ATNM-400 shows efficacy in prostate cancer study

NVS

2025-04-28T12:13:37.000Z · 1 year ago

Actinium’s Actimab-A shows antileukemic activity in AML models

SNDX

Stocktwits

Shotmaker Nov 3, 4:07 PM

$ATNM bought May calls yesterday for .17 ….Can’t get an order at .20 filled today

0 replies

BxxZ Nov 3, 3:03 PM

$ATNM if there was something "in the air" the stock would be 25+ by now !!!!

1 replies

Investfaithfully Nov 3, 2:39 PM

$ATNM SEAGEN was bought by PFIZER!!FOR A WHOPPING 43 Billion!I remember the day!……bidding war…… March 13,2023 …..AQUISITION…..for $229 a share !!!!!!!!!!!!!!!!!! BIDDING WAR ON THE HORIZON FOR ATNM!!!!!!!BBBBBBBUUUUUULLLLIIIIIIISSSSHHHHHHHH FOR SURE!!!!!!

4 replies